Small Cell Lung Cancer
A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer
The purpose of this study is to determine the recommended phase 2 dose of LY3295668 erbumine in participants with platinum-sensitive, extensive-stage small-cell lung cancer.
Your participation in this trial could last up to 20 months, depending on how you and your tumor respond.
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
-Participants must have histological or cytological evidence of a diagnosis of platinum sensitive small cell lung cancer that is extensive stage
-Participants must have adequate organ function
-Participants must have a performance status (PS) of ≤1 on the Eastern Cooperative Oncology Group (ECOG) scale
-Participants must have discontinued previous treatments for cancer.
-Participants must be able to swallow capsules
-Participants must not be currently enrolled in a clinical study
-Participants must not have a serious concomitant systemic disorder
-Participants must not have a symptomatic human immunodeficiency virus infection or symptomatic activated/reactivated hepatitis B or C
-Participants must not have a significant cardiac condition
-Participants must not have previously received an aurora kinase inhibitor